X
AXSM icon

Xponance’s Axsome Therapeutics AXSM Stock Holding History

Xponance’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$659K Buy
3,901
+636
+19% +$110K ﹤0.01% 901
2025
Q4 		$596K Buy
3,265
+76
+2% +$10.6K ﹤0.01% 885
2025
Q3 		$387K Buy
3,189
+35
+1% +$3.94K ﹤0.01% 1056
2025
Q2 		$329K Buy
3,154
+263
+9% +$27.8K ﹤0.01% 1097
2025
Q1 		$337K Buy
2,891
+232
+9% +$26.4K ﹤0.01% 1059
2024
Q4 		$225K Buy
2,659
+277
+12% +$25.5K ﹤0.01% 1250
2024
Q3 		$214K Buy
+2,382
New +$208K ﹤0.01% 1226

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Xponance's AXSM Position: Q1 2026 in Review

Xponance increased its Axsome Therapeutics (AXSM) stake by 19% in Q1 2026, buying an estimated $110K and bringing the position to 3,901 shares worth $659K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Xponance first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Xponance held 3,901 shares of Axsome Therapeutics worth $659K as of Q1 2026.
  • Xponance bought 636 Axsome Therapeutics shares in Q1 2026, an estimated $110K.
  • Axsome Therapeutics made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #901 holding.
  • Xponance first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.